High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients

Brazilian Journal of Otorhinolaryngology

Volumn 81, Issue 6, 2015, Pages 589-597

  Geyer, Lucia Bencke ^a,b   Menna Barreto, Sergio Saldanha ^b,c   Weigert, Liese Loureiro ^a,b   Teixeira, Adriane Ribeiro ^b,d  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSITY OF TORONTO   (Canada)

^d PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Aminoglycosides; Audiometry; Cystic fibrosis

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; AUDIOMETRY; AUDITORY THRESHOLD; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; DISTORTION PRODUCT OTOACOUSTIC EMISSION; FEMALE; HEARING IMPAIRMENT; HIGH FREQUENCY AUDIOMETRY; HUMAN; MALE; TYMPANOMETRY; CASE CONTROL STUDY; CHEMICALLY INDUCED; PATHOPHYSIOLOGY; PURE TONE AUDIOMETRY; SPONTANEOUS OTOACOUSTIC EMISSION; YOUNG ADULT;

ADOLESCENT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; AUDIOMETRY, PURE-TONE; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; FEMALE; HEARING LOSS; HUMANS; MALE; OTOACOUSTIC EMISSIONS, SPONTANEOUS; YOUNG ADULT;

EID: 84947613827     PISSN: 18088694     EISSN: 18088686     Source Type: Journal    
DOI: 10.1016/j.bjorl.2015.08.011     Document Type: Article

References (50)

1. Rubio T., Amaro G., Martínez G. Atención multidisciplinaria a pacientes con fibrosis quística. Rev Cubana Pediatr 1999, 71:228-232.
2. Lubamba B., Dhooghe B., Noel S., Leal T. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem 2012, 45:1132-1144.
3. Dalcin P.T.R. Fibrose Cística. Pneumologia no consultório 2009, 279-291. Artmed, Porto Alegre. S.S. Menna-Barreto (Ed.).
4. Knowles M.R., Stutts M.J., Yankaskas J.R., Gatzy J.T., Boucher R.C. Abnormal respiratory epithelial ion transport in cystic fibrosis. Clin Chest Med 1986, 7:285-297.
5. Wilschanski M., Zielenski J., Markiewicz D., Tsui L.C., Corey M., Levison H., et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene-mutations. J Pediatr 1995, 127:705-710.
6. Proesmans M., Vermeulen F., De Boeck K. What's new in cystic fibrosis? From treating symptoms to correction of the basic defect. Eur J Pediatr 2008, 167:839-849.
7. Mulherin D., Fahy J., Grant W., Keogan M., Kavanagh B., FitzGerald M. Aminoglycoside induced ototoxicity in patients with cystic fibrosis. Ir J Med Sci 1991, 160:173-175.
8. Stavroulaki P., Vossinakis I.C., Dinopoulou D., Doudounakis S., Adamopoulos G., Apostolopoulos N. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis. Arch Otolaryngol Head Neck Surg 2002, 128:150-155.
9. Piltcher O.B., Teixeira V.N., de Oliveira M.W., Scattolin I., Piltcher S.L. The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clinicas de Porto Alegre. Int J Pediatr Otorhinolaryngol 2003, 67:939-941.
10. Cheng A.G., Johnston P.R., Luz J., Uluer A., Fligor B., Licameli G.R., et al. Sensorineural hearing loss in patients with cystic fibrosis. Otolaryngol Head Neck Surg 2009, 141:86-90.
11. Jacob L.C.B., Aguiar F.P., Tomiasi A.A., Tschoeke S.N., Bittencourt R.F. Auditory monitoring in ototoxicity. Braz J Otorhinolaryngol 2006, 72:836-844.
12. Konrad-Martin D., Wilmington D.J., Gordon J.S., Reavis K.M., Fausti S.A. Audiological management of patients receiving aminoglycoside antibiotics. Volta Rev 2005, 105:229-250.
13. American Academy of Audiology [Internet] Position statement and clinical practice guidelines 2009, Available at: http://www.audiology.org/resources/documentlibrary/documents/otomonpositionguideline.pdf [quoted October 2009].
14. Davis J.M., Elfenbein J., Schum R., Bentler R.A. Effects of mild and moderate hearing impairments on language, education and psychosocial behavior of children. J Speech Hear Disord 1986, 51:53-62.
15. Fausti S.A., Rappaport B.Z., Schechter M.A., Frey R.H., Ward T.T., Brummett R.E. Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: selected cases studies. Am J Otolaryngol 1984, 5:177-182.
16. Klagenberg K.F., Oliva F.C., Gonçalves C.G.O., Lacerda A.B.M., Garofani V.G., Zeigelboim B.S. Audiometria de altas frequências no diagnóstico complementar em audiologia: uma revisão da literatura nacional. Rev Soc Bras Fonoaudiol 2011, 16:109-114.
17. Fausti S.A., Henry J.A., Schaffer H.I., Olson D.J., Frey R.H., McDonald W.J. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 1992, 165:1026-1032.
18. Pedersen S.S., Jensen T., Osterhammel D., Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob Agents Chemother 1987, 31:594-599.
19. McRorie T.I., Bosso J., Randolph L. Aminoglycoside ototoxicity in cystic fibrosis. Am J Dis Child 1989, 143:1328-1332.
20. Mulheran M., Degg C., Burr S., Morgan D.W., Stableforth D.E. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrob Agents Chemother 2001, 45:2502-2509.
21. Mulheran M., Hyman-Taylor P., Tan K.H., Lewis S., Stableforth D., Knox A., et al. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrob Agents Chemother 2006, 50:2293-2299.
22. Toral-Martiñón R., Shkurovich-Bialik P., Collado-Corona M.A., Mora-Magaña I., Goldgrub-Listopad S., Shkurovich-Zaslavsky M. Distortion product otoacoustic emissions test is useful in children undergoing cisplatin treatment. Arch Med Res 2003, 34:205-208.
23. Knight K.R., Kraemer D.F., Winter C., Neuwelt E.A. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007, 25:1190-1195.
24. Mulheran M., Degg C. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. Br J Audiol 1997, 31:5-9.
25. Ozturan O., Jerger J., Lew H., Lynch G.R. Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions. Auris Nasus Larynx 1996, 23:147-151.
26. Littman T.A., Magruder A., Strother D.R. Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: pediatric case study. J Am Acad Audiol 1998, 9:257-262.
27. Garcia A.P., Iório M.C.M., Petrilli A.S. Monitoramento da audição de pacientes expostos à cisplatina. Braz J Otorhinolaryngol 2003, 69:215-221.
28. Reavis K.M., Phillips D.S., Fausti S.A., Gordon J.S., Helt W.J., Wilmington D., et al. Factors affecting sensitivity of distortion product otoacoustic emissions to ototoxic hearing loss. Ear Hear 2008, 29:875-893.
29. Abujamra A.L., Escosteguy J.R., Dall'Igna C., Manica D., Cigana L.F., Coradini P., et al. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy. Pediatr Blood Cancer 2013, 60:474-478.
30. Jerger J. Clinical experience with impedance audiometry. Arch Otolaryngol 1970, 92:311-324.
31. Pedalini M.E.B., Sanchez T.G., D'Antonio A., D'Antonio W., Balbani A., Hachiya A., et al. Média dos limiares tonais na audiometria de alta frequência em indivíduos normais de 4 a 60 anos. Pró-Fono 2000, 12:17-20.
32. Sahyeb D.R., Costa Filho O.A., Alvarenga K.F. Audiometria de alta frequência: estudo com indivíduos audiologicamente normais. Braz J Otorhinolaryngol 2003, 69:93-99.
33. Sá L.C.B., Lima M.A.M.T., Tomita S., Frota S.M.M.C., Santos G.A., Garcia T.R. Avaliação dos limiares de audibilidade das altas frequências em indivíduos entre 18 e 29 sem queixas otológicas. Braz J Otorhinolaryngol 2007, 73:215-225.
34. Carvallo R.M.M., Koga M.C., Carvalho M., Ishida I.M. Limiares auditivos para altas frequências em adultos sem queixa auditiva. Acta ORL 2007, 25:62-66.
35. Azevedo M.F. Emissões otoacústicas. Conhecimentos essenciais para entender bem emissões otoacústicas e BERA 2003, 35-84. Pulso, São José dos Campos. M.S. Figueiredo (Ed.).
36. Chauhan R.S., Saxena R.K., Varshey S. The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss. Ear Nose Throat J 2011, 90:218-222.
37. Beahan N., Kei J., Driscoll C., Charles B., Khan A. High-frequency pure-tone audiometry in children: a test-retest reliability study relative ototoxic criteria. Ear Hear 2012, 33:104-111.
38. Davey P.G., Jabeen F.J., Harpur E.S., Shenoi P.M., Geddes A.M. A controlled study of reliability of pure tone audiometry for the detection of gentamicin auditory toxicity. J Laryngol Otol 1983, 97:27-36.
39. Leigh-Paffenroth E., Reavis K.M., Gordon J.S., Dunckley K.T., Fausti S.A., Konrad-Martin D. Objective measures of ototoxicity. Perspect Hear Hear Disord Res Diagn 2005, 9:10-16.
40. Weigert L.L., Piltcher O.B., Procianoy E.F.A., Buss C.H., Menna-Barreto S.S. Avaliação do uso da audiometria em frequências ultra-altas em pacientes submetidos ao uso de ototóxicos. Bras Med 2013, 50:264-273.
41. Martins L.M.N., Camargos P.A.M., Becker H.M.G., Becker C.G., Guimarães H.M.G. Hearing loss in cystic fibrosis. Int J Pediatr Otorhinolaryngol 2010, 74:469-473.
42. Al-Malky G., Suri R., Dawson S.J., Sirimanna T., Kemp D. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: a study using extended high-frequency audiometry and distortion product otoacoustic emissions. Int J Audiol 2011, 50:112-122.
43. Katbamna B., Homnick D.N., Marks J.H. Contralateral suppression of distortion product otoacoustic emissions in children with cystic fibrosis: effects of tobramycin. J Am Acad Audiol 1998, 9:172-178.
44. Katbamna B., Homnick D.N., Marks J.H. Effects of chronic tobramycin treatment on distortion product emissions. Ear Hear 1999, 20:393-402.
45. Arnold D.J., Lonsbury-Martin B.L., Martin G.K. High-frequency hearing influences lower-frequency distortion-product otoacoustic emissions. Arch Otolaryngol Head Neck Surg 1999, 125:215-222.
46. Moore R.D., Smith C.R., Lietman P.S. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984, 149:23-30.
47. Govaerts P.J., Claes J., Van De Heyning P.H., Jorens P.G., Marquet G., De Broe M.E. Aminoglycoside-induced ototoxicity. Toxicol Lett 1990, 52:227-251.
48. Tan K.H.V., Mulheran M., Knox A.J., Smyth A.R. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:819-823.
49. de Groot R., Smith A.L. Antibiotic pharmacokinetics in cystic fibrosis differences and clinical significance. Clin Pharmacokinet 1987, 13:228-253.
50. Spino M. Pharmacokinetics of drugs in cystic fibrosis. Clin Rev Allergy 1991, 9:169-210.